DailyUpdates for R&D News
LeadDiscovery constantly monitors the websites of Pharmaceutical and Biotech companies. Press releases relating to drug development activity are featured on DailyUpdates providing timely alerts to new clinical data, pipeline advances and regulatory news. Press releases are linked to their original source.
Latest News
- First patient dosed in new phase III study targeted towards a future clinical indication expansion for Zubsolv
- Sobi gets FDA approval to manufacture substance for Kineret® with partner Boehringer Ingelheim
- AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA® (adalimumab) for Rheumatoid Arthritis
- Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease
- Teva and Active Biotech Report Positive Results from Phase IIa Study of Laquinimod in Active Lupus Nephritis
- Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer\'s Disease
- New Data Showed LIVALO® (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1c Levels in HIV-infected Adults with Dyslipidemia
- Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma
- ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis
- New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF
- Boehringer Ingelheim’s investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients
- AbbVie and Eisai Announce HUMIRA® Pre-filled Syringe 40 mg / 0.8 mL, a Fully Human Monoclonal Anti-TNF-α Antibody Formulation, Has Received Approval for the Treatment of Moderate to Severe Ulcerative Colitis (UC) in Japan
- Updated Results of Two Phase 2 ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
- Approval for Additional Indication for Atrial Fibrillation (Tachycardiac) MAINTATE Tablets: Selective β1 Blocker
- Novartis drug Jakavi® improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease
- Roche\'s RoACTEMRA shows long-term efficacy in monotherapy and also benefits in early rheumatoid arthritis
- Roche\'s Avastin approved in Japan for treatment of the most aggressive form of brain cancer
- Axial spondyloarthritis patients treated with certolizumab pegol reported improvements in pain, fatigue and physical function, and increased workplace and household productivity
- RAPID™-PsA study highlights burden of psoriatic arthritis and showed that patients treated with certolizumab pegol reported improvements in pain and fatigue, and increased productivity at work and within the home
- Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
- Subcutaneous Self-Administered Methotrexate for Rheumatoid Arthritis Demonstrated Significantly Greater Bioavailability Over Current Standard of Care
- IMMUNOMEDICS PRESENTS EPRATUZUMAB’S MECHANISM OF ACTION IN SYSTEMIC LUPUS ERYTHEMATOSUS
- COMBINATION OF 90Y-EPRATUZUMAB AND VELTUZUMAB IS ACTIVE IN NON-HODGKIN LYMPHOMA
- IntelGenx Announces FDA Acceptance Of New Drug Application For Anti-Migraine VersaFilm(TM) Oral Film Product
- Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
- Santarus and Pharming Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application